Journal rankings · indicator year 2014
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2014
Oncology journal rankings 2014
179 ranked journals · Subfield in Medicine
Oncology has 179 ranked journals in 2014. The median journal has an OJR of 0.97, below the world average of 1.00, unchanged on 2013; Q1 starts at OJR 1.50. The top three are CA A Cancer Journal for Clinicians, Cancer Cell, and The Lancet Oncology.
Ranks and citation indicators: 2014. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2011–2013, the window the 2014 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery734
- Pulmonary and Respiratory Medicine283
- Public Health, Environmental and Occupational Health244
- Cardiology and Cardiovascular Medicine227
- Oncology179
- Infectious Diseases173
- Epidemiology166
- Neurology138
- Endocrinology, Diabetes and Metabolism136
- Radiology, Nuclear Medicine and Imaging136
- Physiology127
- Psychiatry and Mental health119
Show all 42 subfields
- Orthopedics and Sports Medicine89
- Pediatrics, Perinatology and Child Health80
- Ophthalmology75
- Dermatology74
- Hematology69
- Rheumatology59
- Obstetrics and Gynecology58
- Nephrology51
- Pharmacology43
- Reproductive Medicine43
- Complementary and alternative medicine41
- Emergency Medicine36
- Geriatrics and Gerontology35
- Otorhinolaryngology34
- Rehabilitation25
- Critical Care and Intensive Care Medicine22
- Pathology and Forensic Medicine21
- Genetics19
- Hepatology18
- Immunology and Allergy16
- Anesthesiology and Pain Medicine12
- Urology12
- Gastroenterology6
- Internal Medicine5
- Transplantation3
- Family Practice2
- Health Informatics1
- Anatomy0
- Biochemistry0
- Microbiology0
179 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2013. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2011–2013, the window the 2014 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2011–2013 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2005 to 2014. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 73.87Q1 | 135.08 75.15 down from 2013 | 74 | 100% | $4,330 | ||
2Cancer CellCell Press · Netherlands | 6.71Q1 | 18.63 1.39 down from 2013 | 513 | 100% | $10,400 | ||
3The Lancet OncologyElsevier BV · United Kingdom | 6.57Q1 | 15.36 0.53 down from 2013 | 896 | 14% | $7,280 | ||
4Nature MedicineNature Portfolio · United States | 5.71Q1 | 13.69 1.01 up from 2013 | 1,425 | 38% | $12,690 | ||
5Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 5.42Q1 | 13.64 0.54 up from 2013 | 2,698 | 7% | — | ||
6Seminars in Cancer BiologyElsevier BV · United States | 3.89Q1 | 11.07 0.01 down from 2013 | 167 | 31% | $6,060 | ||
7Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 3.50Q1 | 9.46 0.32 down from 2013 | 2,298 | 54% | — | ||
8JNCI Journal of the National Cancer InstituteOxford University Press · United States | 3.47Q1 | 7.80 3.73 down from 2013 | 776 | 56% | $5,436 | ||
9Clinical Pharmacology & TherapeuticsWiley · United States | 3.11Q1 | 6.58 0.18 up from 2013 | 808 | 24% | $4,410 | ||
10Annals of OncologyElsevier BV · Netherlands | 2.87Q1 | 7.64 0.85 up from 2013 | 1,610 | 100% | $5,080 | ||
11Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 2.77Q1 | 5.86 0.43 up from 2013 | 333 | 74% | — | ||
12Cancer Treatment ReviewsElsevier BV · United Kingdom | 2.52Q1 | 9.10 1.45 up from 2013 | 308 | 20% | $4,910 | ||
13CancerWiley · United States | 2.36Q1 | 5.43 0.41 down from 2013 | 1,903 | 71% | $4,790 | ||
14Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 2.34Q1 | 6.05 0.68 down from 2013 | 835 | 52% | — | ||
15British Journal of CancerSpringer Nature · United Kingdom | 2.27Q1 | 5.82 0.15 down from 2013 | 1,928 | 100% | $5,190 | ||
16European Journal of EpidemiologySpringer Science+Business Media · Italy | 2.25Q1 | 5.02 0.16 down from 2013 | 308 | 40% | $3,690 | ||
17Cancer DiscoveryAmerican Association for Cancer Research · United States | 2.24Q1 | 5.16 0.03 up from 2013 | 924 | 21% | — | ||
18Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 2.23Q1 | 5.09 0.47 down from 2013 | 103 | 42% | $4,090 | ||
19European Journal of CancerElsevier BV · United Kingdom | 2.19Q1 | 6.38 1.16 up from 2013 | 1,254 | 5% | $4,270 | ||
20Journal of Hematology & OncologyOABioMed Central · United Kingdom | 2.18Q1 | 6.45 0.17 up from 2013 | 229 | 100% | $4,990 | ||
21The OncologistOAAlphaMed Press · United Kingdom | 2.05Q1 | 4.99 0.60 down from 2013 | 668 | 96% | $3,852 | ||
22International Journal of CancerWiley · United States | 2.04Q1 | 5.37 0.18 up from 2013 | 1,956 | 75% | $5,030 | ||
23Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 2.02Q1 | 5.19 0.22 up from 2013 | 304 | 15% | — | ||
24Cancer Immunology ResearchAmerican Association for Cancer Research · United States | 2.00Q1 | 5.30no 2013 value | 74 | 67% | — | — | |
25Cancer ControlOASAGE Publishing · United States | 1.99Q1 | 5.11 1.03 up from 2013 | 93 | 45% | $2,650 | ||
26The Cancer JournalLippincott Williams & Wilkins · United States | 1.95Q1 | 5.49 0.37 up from 2013 | 233 | 35% | — | ||
27Seminars in OncologyElsevier BV · United States | 1.94Q1 | 4.81 0.26 down from 2013 | 256 | 27% | $3,550 | ||
28Cancer Research and TreatmentOAKorean Cancer Association · South Korea | 1.93Q1 | 5.51 0.78 up from 2013 | 125 | 100% | — | ||
29Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.90Q1 | 4.36 0.21 up from 2013 | 714 | 7% | — | ||
30Cancer Epidemiology Biomarkers & PreventionAmerican Association for Cancer Research · United States | 1.90Q1 | 4.83 0.30 down from 2013 | 931 | 39% | — | ||
31Cancer Prevention ResearchAmerican Association for Cancer Research · United States | 1.87Q1 | 4.40 1.43 down from 2013 | 587 | 70% | — | ||
32Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.81Q1 | 5.04 0.61 up from 2013 | 340 | 14% | $4,190 | ||
33Breast Cancer ResearchOABioMed Central · United Kingdom | 1.78Q1 | 4.87 0.56 down from 2013 | 738 | 100% | $4,190 | ||
34Frontiers in OncologyOAFrontiers Media · Switzerland | 1.71Q1 | 4.66 1.18 up from 2013 | 603 | 100% | $3,801 | ||
35Archives of Pathology & Laboratory MedicineOAAmerican Medical Association · United States | 1.68Q1 | 3.99 0.47 up from 2013 | 685 | 36% | — | ||
36Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.67Q1 | 4.18 0.49 down from 2013 | 451 | 19% | — | ||
37OncologyKarger Publishers · Switzerland | 1.65Q1 | 5.02 1.82 up from 2013 | 370 | 22% | — | ||
38Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.64Q1 | 5.22 0.24 up from 2013 | 524 | 100% | $4,590 | ||
39BMC CancerOABioMed Central · United Kingdom | 1.63Q1 | 4.54 0.10 up from 2013 | 1,772 | 100% | $3,390 | ||
40Clinical and Translational GastroenterologyOALippincott Williams & Wilkins · United States | 1.61Q1 | 3.89 1.67 up from 2013 | 41 | 100% | $2,800 | ||
41Cancer MicroenvironmentSpringer Science+Business Media · Netherlands | 1.61Q1 | 3.78 0.55 down from 2013 | 80 | 100% | $3,860 | ||
42Journal of Cancer EpidemiologyHindawi Publishing Corporation · United Kingdom | 1.58Q1 | 4.31 1.16 up from 2013 | 57 | 100% | $950 | ||
43Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 1.57Q1 | 4.75 0.63 up from 2013 | 158 | 33% | — | ||
44Therapeutic Advances in Medical OncologyOASAGE Publishing · United Kingdom | 1.56Q1 | 3.04 1.73 down from 2013 | 82 | 100% | $2,800 | ||
45Current Oncology ReportsSpringer Science+Business Media · United States | 1.50Q1 | 3.58 0.17 up from 2013 | 205 | 17% | $5,090 | ||
46JNCI MonographsOxford University Press · United Kingdom | 1.49Q2 | 2.75 0.12 down from 2013 | 104 | 90% | — | ||
47European Journal of Cancer PreventionLippincott Williams & Wilkins · United States | 1.48Q2 | 3.85 0.87 up from 2013 | 166 | 16% | — | ||
48Journal of Cancer SurvivorshipSpringer Science+Business Media · United States | 1.48Q2 | 3.78 0.94 down from 2013 | 157 | 53% | $4,790 | ||
49CytotherapyElsevier BV · United Kingdom | 1.48Q2 | 4.14 0.17 up from 2013 | 418 | 11% | $3,300 | ||
50Current Treatment Options in OncologySpringer Science+Business Media · United States | 1.45Q2 | 3.80 0.47 down from 2013 | 129 | 17% | $4,890 |
Subfields of Medicine, with Oncology highlighted.
- Surgery734
- Pulmonary and Respiratory Medicine283
- Public Health, Environmental and Occupational Health244
- Cardiology and Cardiovascular Medicine227
- Oncology179
- Infectious Diseases173
- Epidemiology166
- Neurology138
- Endocrinology, Diabetes and Metabolism136
- Radiology, Nuclear Medicine and Imaging136
- Physiology127
- Psychiatry and Mental health119
- Orthopedics and Sports Medicine89
- Pediatrics, Perinatology and Child Health80
- Ophthalmology75
- Dermatology74
- Hematology69
- Rheumatology59
- Obstetrics and Gynecology58
- Nephrology51
- Pharmacology43
- Reproductive Medicine43
- Complementary and alternative medicine41
- Emergency Medicine36
- Geriatrics and Gerontology35
- Otorhinolaryngology34
- Rehabilitation25
- Critical Care and Intensive Care Medicine22
- Pathology and Forensic Medicine21
- Genetics19
- Hepatology18
- Immunology and Allergy16
- Anesthesiology and Pain Medicine12
- Urology12
- Gastroenterology6
- Internal Medicine5
- Transplantation3
- Family Practice2
- Health Informatics1
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
Citations made in 2014. Corpus-wide, 77.7% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
53 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2011–2013, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2014. Publication window: 2011–2013. How these summaries are calculated
- Ranked journals
- 179
- Window papers (baseline)
- 93,912 +14.4% from indicator year 2011
- Median OJR
- 0.972 +2.3% from indicator year 2011
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2011–2013 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.